NextCure (NASDAQ:NXTC) Stock Price Up 7.7% – Time to Buy?Defense World · Sep 9, 2026
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001PRNewsWire · Aug 10, 2026
NextCure, Inc. (NASDAQ:NXTC) Sees Large Increase in Short InterestDefense World · Jul 27, 2026NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.95 | -$2.80 | Miss |
| May 7, 2026 | -$1.81 | -$1.87 | Miss |
| Mar 5, 2026 | -$2.26 | -$0.81 | Beat |
| Nov 5, 2025 | -$4.06 | -$3.22 | Beat |
| Aug 7, 2025 | -$4.62 | -$11.29 | Miss |
| May 1, 2025 | -$4.80 | -$4.68 | Beat |